{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li DH"],"funding":["National Natural Science Foundation of China"],"pagination":["25-30"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4448478"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(1)"],"pubmed_abstract":["<h4>Background</h4>A neuroendocrine tumor (NET) is a special kind of epithelial tumor with predominant neuroendocrine differentiation, which arises throughout the body, including the lung. A subpopulation of lung cancer patients suffer from the mixed (combined) form of NET with components of non-neuroendocrine carcinoma. However, the clinical characteristics of the mixed form of NET are not well established.<h4>Methods</h4>We analyzed 2501 consecutive cases of primary lung cancer from 2009 to 2011. The diagnosis, histology, therapy, and outcome were collected.<h4>Results</h4>A total of 22 patients were enrolled. The occurrence rate of lung cancer was 0.9%. Neither gender (1.2% and 0.3% for male and female, respectively, P = 0.35) nor age (0.6% and 1.3% for patients aged ≤60 and >60, respectively, P = 0.13) was associated with the onset of this disease; however it has become more frequent in recent years (0.6% and 1.6% at the time ≤ and >2010 respectively, P = 0.03). This cohort of 22 patients had a median survival of 60.0 months (95% confidence interval: 14.3-105.6 months). Patients with metastatic disease (60 months and not reached [NR], P = 0.18) or a small-cell lung cancer component tended to have a shorter survival (35 months and NR, P = 0.16). Patients who underwent surgery had a significantly longer survival period (NR and 17.0 months, P = 0.001).<h4>Conclusions</h4>A mixed form of NET in the lung is a rare disease. While stage and histology might influence prognosis, surgery is the critical factor for long-term survival."],"journal":["Thoracic cancer"],"pubmed_title":["Clinical characteristics of the mixed form of neuroendocrine tumor in the lung: A retrospective study in 2501 lung cancer cases."],"pmcid":["PMC4448478"],"funding_grant_id":["81272684"],"pubmed_authors":["Ding ZY","Wang C","Huang H","Li DH","Chen HJ"],"additional_accession":[]},"is_claimable":false,"name":"Clinical characteristics of the mixed form of neuroendocrine tumor in the lung: A retrospective study in 2501 lung cancer cases.","description":"<h4>Background</h4>A neuroendocrine tumor (NET) is a special kind of epithelial tumor with predominant neuroendocrine differentiation, which arises throughout the body, including the lung. A subpopulation of lung cancer patients suffer from the mixed (combined) form of NET with components of non-neuroendocrine carcinoma. However, the clinical characteristics of the mixed form of NET are not well established.<h4>Methods</h4>We analyzed 2501 consecutive cases of primary lung cancer from 2009 to 2011. The diagnosis, histology, therapy, and outcome were collected.<h4>Results</h4>A total of 22 patients were enrolled. The occurrence rate of lung cancer was 0.9%. Neither gender (1.2% and 0.3% for male and female, respectively, P = 0.35) nor age (0.6% and 1.3% for patients aged ≤60 and >60, respectively, P = 0.13) was associated with the onset of this disease; however it has become more frequent in recent years (0.6% and 1.6% at the time ≤ and >2010 respectively, P = 0.03). This cohort of 22 patients had a median survival of 60.0 months (95% confidence interval: 14.3-105.6 months). Patients with metastatic disease (60 months and not reached [NR], P = 0.18) or a small-cell lung cancer component tended to have a shorter survival (35 months and NR, P = 0.16). Patients who underwent surgery had a significantly longer survival period (NR and 17.0 months, P = 0.001).<h4>Conclusions</h4>A mixed form of NET in the lung is a rare disease. While stage and histology might influence prognosis, surgery is the critical factor for long-term survival.","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jan","modification":"2025-04-18T16:39:50.693Z","creation":"2019-03-27T01:52:22Z"},"accession":"S-EPMC4448478","cross_references":{"pubmed":["26273331"],"doi":["10.1111/1759-7714.12128"]}}